Department of Biotechnology, Indian Institute of Technology Roorkee, 247667, India.
Department of Biotechnology, Indian Institute of Technology Roorkee, 247667, India.
Biochimie. 2018 Jun;149:18-33. doi: 10.1016/j.biochi.2018.03.012. Epub 2018 Mar 29.
Malonyl-CoA:acyl carrier protein transacylase (FabD), being an essential enzyme of the FAS II pathway, is an attractive target for developing broad-spectrum antibiotics. It performs initiation reaction to form malonyl-ACP, which is a key building block in fatty acid biosynthesis. In this study, we have characterized the FabD from drug-resistant pathogen Moraxella catarrhalis (McFabD). More importantly, we have shown the binding of McFabD with three new compounds from the class of aporphine alkaloids. ITC based binding studies have shown that apomorphine is binding to McFabD with a stronger affinity (K = 4.87 μM) as compared to boldine (K = 7.19 μM) and magnoflorine (K = 11.7 μM). The possible mechanism of fluorescence quenching is found to be static with K values higher than 10, which was associated with the ground state complex formation of aporphine alkaloids with McFabD. Conformational changes observed in the secondary and tertiary structure marked by the loss of helical content during the course of interactions. Molecular docking based studies have predicted the binding mode of aporphine alkaloids and it is found that these compounds are interacting in a similar fashion as known inhibitor corytuberine is interacting with McFabD. The analysis of docking poses have revealed that His 210, Leu102, Gln19, Ser101 and Arg 126 are critical residues, which may play important role in binding. The growth inhibition assay has shown that apomorphine has better MIC value (4-8 μg/ml) against Moraxella catarrhalis as compared to boldine and magnoflorine. Therefore, the current study suggests that aporphine alkaloids can act as antibacterial agents and possible target of these compounds could be FabD enzyme from the FAS II pathway, and apomorphine scaffold will be more suitable among these compounds for potential development of antibacterial agents.
丙二酰辅酶 A:酰基载体蛋白转酰基酶(FabD)作为 FAS II 途径的必需酶,是开发广谱抗生素的有吸引力的靶标。它执行起始反应以形成丙二酰-ACP,这是脂肪酸生物合成的关键构建块。在这项研究中,我们已经对耐药病原体粘膜炎莫拉氏菌(McFabD)的 FabD 进行了表征。更重要的是,我们已经展示了 McFabD 与阿朴啡生物碱类的三种新化合物的结合。ITC 基于结合研究表明,阿朴吗啡与 McFabD 的结合亲和力更强(K=4.87μM),而波多尼(K=7.19μM)和厚朴碱(K=11.7μM)则较弱。发现荧光猝灭的可能机制是静态的,K 值高于 10,这与阿朴啡生物碱与 McFabD 形成的基态复合物有关。在相互作用过程中,二级和三级结构中观察到的构象变化表明螺旋含量的丧失。基于对接的研究预测了阿朴啡生物碱的结合模式,发现这些化合物的相互作用方式与已知抑制剂 Corytuberine 与 McFabD 的相互作用方式相似。对接构象的分析表明,His210、Leu102、Gln19、Ser101 和 Arg126 是关键残基,它们可能在结合中起重要作用。生长抑制试验表明,与波多尼和厚朴碱相比,阿朴吗啡对粘膜炎莫拉氏菌的 MIC 值(4-8μg/ml)更好。因此,目前的研究表明,阿朴啡生物碱可以作为抗菌剂,这些化合物的可能靶点可能是 FAS II 途径中的 FabD 酶,而阿朴啡骨架在这些化合物中更适合作为潜在的抗菌剂开发。